.png)
Faron Pharmaceuticals' (LON:FARN) Dr Markku Jalkanen speaks to Proactive London's Andrew Scott following a successful virtual R&D day this week.
He also reports on the continued progress for two of its clinical stage programmes, Clevegen and Traumakine, including the just-announced HIBISCUS ( Human Interferon Beta In Severe CoronavirUS) trial which will focus on intensive care patients with ARDS caused by viral infection such as coronavirus and influenza.
